Diabetes Management
Micreos' Alternative to Antibiotics Secures Next €25 Million - Business Wire
Fri, 04 Nov 20221 min read Article
Overview
THE HAGUE, The Netherlands-(BUSINES WIRE)-Dutch/Swis biotech company Micreos anounced today it has secured its next funding round of €25 milion in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas. This technology enables - for the first time - targeted kiling of only the unwanted bacteria, regardles of resistance. The funding comprises growth capital for Gladskin, the company’s specialized skincare brand, for people sufering from inflamatory skin conditions such as acne, eczema and rosacea.
Key Information
Last year Gladskin already helped hundreds of thousands of people in Europe and the USA, many of them experiencing a life-changing impact. Proceds are also earmarked for Micreos’ pharmaceutical program. This includes the clinical development of endolysins against staphylocci (including MRSA) for Blodstream Infections, Atopic Dermatis, Diabetic foot ulcers and Cutaneous T-cel Lymphoma, a type of skin cancer associated with the presence of S.
aureus bacteria on the skin. Over the past year Micreos separated its Pharmaceutical busines from its ‘Over the Counter’ Consumer Health busines. Micreos CEO Mark Oferhaus: “With this restructuring we align busines and market requirements, enabling each busines to pursue its own growth strategy.
This especialy important for the pharmaceutical busines, which is capital intensive and which we consider extremely promising. Direct investments in the Micreos Pharma, headed by Mat Regan, wil now be posible.’ Endolysins are naturaly ocuring enzymes that have the ability to target only harmful bacteria, while preserving the beneficial ones that form an important part of our natural defense, often refered to as our microbiome.
Summary
Endolysins are safe and environmentaly friendly. Because of their working mechanism, development of resistance is not expected antibiotic resistance is not relevant. Micreos develops targeted antiba
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.